<DOC>
	<DOCNO>NCT01978600</DOCNO>
	<brief_summary>The purpose study evaluate intraocular pressure ( IOP ) 24-hour period use Simbrinza™ topical ophthalmic suspension .</brief_summary>
	<brief_title>Evaluation Intraocular Pressure Using Simbrinza™ Patients With Open-Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description>This study consist two phase , Screening/Eligibility Phase Treatment Phase . Both phase require patient complete overnight stay .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<criteria>Clinical diagnosis either openangle glaucoma ocular hypertension eye . Willing able attend studyrelated visit house overnight clinical site study assessment . Must sign Informed Consent form . Other protocolspecified inclusion criterion may apply . Women childbearing potential pregnant , breastfeeding , use adequate birth control . Severe central visual field loss either eye . Chronic , recurrent severe inflammatory eye disease . Ocular trauma ocular surgery within past 6 month . Ocular infection ocular inflammation within past 3 month . Clinically significant progressive retinal disease . Other ocular pathology , include severe dry eye , may opinion investigator preclude administration study medication . Any condition include severe illness would make patient , opinion Investigator , unsuitable study . Any medical condition would preclude safe administration topical betablocker . Can safely discontinue glucocorticoid administer route . Other protocolspecified exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Open-Angle Glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
	<keyword>Simbrinza™</keyword>
	<keyword>Intraocular Pressure</keyword>
</DOC>